Nurix Therapeutics appointed Dr. Arati V. Rao as Chief Medical Officer, leveraging her 20+ years of experience in oncology and clinical development. She will oversee Nurix's clinical programs, including the advancement of bexobrutideg in collaboration with Roche. Dr. Rao's background includes leadership roles at Pfizer, Seagen, and Kite-Gilead, contributing to significant drug approvals. Her expertise is expected to accelerate Nurix's pipeline development and regulatory progress.
Nurix Therapeutics news comes as 67 of 150 priced Health-sector US stocks on Pluang rose while 75 fell, as of Nov 11, 2026 19:11 WIB. For readers following Health-sector stocks, DNA (Ginkgo Bioworks Holdings Inc) gained 4.00% to USD 12.49 with a typical hold time of 9 days and balanced buy/sell activity. RXRX (Recursion Pharmaceuticals Inc) rose 3.93% to USD 3.70 with 100% buy order activity and a typical hold time of 23 days, while REGN (Regeneron Pharmaceuticals Inc) declined 3.61% to USD 883.02 with 100% buy order activity and a typical hold time of 108 days.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
